| 2026-09-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) tevapharm.com ↗ |
| 2026-09-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) tevapharm.com ↗ |
| 2026-06-24 |
Shanghai Henlius Biotech |
Organon CANADA and henlius Expand Access to Denosumab Treatments With LAUNCH OF BILDYOS® (Denosumab Injection) and TUZEMTY® (Denosumab Injection), Biosimilars to PROLIA and XGEVA henlius.com ↗ |
| 2026-04-07 |
Apotex Inc. |
Apotex Strengthens Osteoporosis Care in Canada with Health Canada's Approval of DENOZA™, a Denosumab Biosimilar apotex.com ↗ |
| 2026-03-30 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) tevapharm.com ↗ |
| 2026-03-30 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) tevapharm.com ↗ |
| 2026-03-24 |
Shanghai Henlius Biotech |
Health Canada Approves Henlius’ BILDYOS® (Denosumab Injection) and TUZEMTY® (Denosumab Injection), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively henlius.com ↗ |
| 2026-01-19 |
Roxane Laboratories |
Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively hikma.com ↗ |
| 2025-12-22 |
Impax Laboratories, LLC |
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® amneal.com ↗ |
| 2025-12-02 |
Shanghai Henlius Biotech |
Henlius’ Denosumab HLX14 New Drug Application Accepted by NMPA henlius.com ↗ |
| 2025-12-01 |
Fresenius Kabi |
Fresenius Launches Denosumab Biosimilars in EU fresenius.com ↗ |
| 2025-12-01 |
Fresenius Kabi |
Fresenius Launches Denosumab Biosimilars in EU fresenius.com ↗ |
| 2025-12-01 |
Fresenius Kabi |
Fresenius Launches Denosumab Biosimilars in Europe
BAD HOMBURG, December 1, 2025 – Fresenius Kabi, part of the global healthcare company Fresenius, announced today the European launch of its denosumab biosimilars, Conexxence® (denosumab) and Bomyntra® (denosumab). fresenius-kabi.com ↗ |
| 2025-11-25 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® tevapharm.com ↗ |
| 2025-11-25 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® tevapharm.com ↗ |
| 2025-11-24 |
Alvotech Swiss AG |
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area alvotech.com ↗ |
| 2025-11-12 |
Shanghai Henlius Biotech |
The UK Medicines and Healthcare Products Regulatory Agency Approves BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively henlius.com ↗ |
| 2025-10-30 |
Celltrion |
U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) celltrion.com ↗ |
| 2025-09-29 |
Roxane Laboratories |
Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively hikma.com ↗ |
| 2025-09-29 |
Gedeon Richter Ltd. |
Richter and Hikma receive FDA approval for denosumab biosimilars Enoby™ and Xtrenbo™, referencing Prolia® and Xgeva®, respectively gedeonrichter.com ↗ |
| 2025-09-22 |
Alvotech Swiss AG |
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva® alvotech.com ↗ |
| 2025-09-19 |
Organon and Co |
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively organon.com ↗ |
| 2025-09-19 |
Shanghai Henlius Biotech |
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively henlius.com ↗ |
| 2025-09-02 |
Organon and Co |
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively organon.com ↗ |
| 2025-09-02 |
Shanghai Henlius Biotech |
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively henlius.com ↗ |
| 2025-07-28 |
Shanghai Henlius Biotech |
CHMP Recommends EU Approval of Henlius’ Denosumab Biosimilar HLX14 henlius.com ↗ |
| 2025-07-08 |
Celltrion |
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo) celltrion.com ↗ |
| 2025-07-07 |
Biocon Biologics UK Ltd |
Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars bioconbiologics.com ↗ |
| 2025-07-03 |
Fresenius Kabi |
Fresenius expands Biopharma Portfolio in the U.S. with Denosumab Biosimilars availability fresenius.com ↗ |
| 2025-07-02 |
Fresenius Kabi |
mAbxience Announces European Commission Approval of Denosumab Biosimilars
mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®. fresenius-kabi.com ↗ |
| 2025-07-01 |
Gedeon Richter Ltd. |
Richter receives European Commission approval for Junod® and Yaxwer®, its biosimilar denosumab products for bone disease and osteoporosis gedeonrichter.com ↗ |
| 2025-07-01 |
Fresenius Kabi |
Fresenius expands Biopharma Portfolio in the U.S. with Denosumab Biosimilars availability fresenius.com ↗ |
| 2025-06-30 |
Fresenius Kabi |
Fresenius Expands Biosimilars Portfolio with the availability of their denosumab biosimilars in the U.S.
Fresenius Kabi’s fifth and sixth biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) are now available in the U.S. for all approved indications for their respective reference products, Prolia® (denosumab) and Xgeva® (denosumab). fresenius-kabi.com ↗ |
| 2025-06-02 |
Sandoz |
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1] sandoz.com ↗ |
| 2025-05-27 |
Fresenius Kabi |
Denosumab CHMP Positive Opinion fresenius.com ↗ |
| 2025-05-27 |
Fresenius Kabi |
Denosumab CHMP Positive Opinion fresenius.com ↗ |
| 2025-05-27 |
Fresenius Kabi |
Fresenius Receives Positive CHMP Opinion for their Denosumab Biosimilar Candidates
Fresenius announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the marketing authorization of its biosimilar candidates to Prolia® (denosumab) and Xgeva® (denosumab). fresenius-kabi.com ↗ |
| 2025-04-26 |
Biocon Biologics UK Ltd |
Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe bioconbiologics.com ↗ |
| 2025-04-25 |
Gedeon Richter Ltd. |
Richter Receives Positive Opinion from CHMP for Marketing Authorisation for Junod® and Yaxwer®, its Biosimilar Denosumab Products for Bone Disease and Osteoporosis gedeonrichter.com ↗ |
| 2025-03-26 |
Fresenius Kabi |
Fresenius Receives FDA approval for their Denosumab Biosimilars and Secures Global Settlement fresenius.com ↗ |
| 2025-03-26 |
Fresenius Kabi |
Fresenius Receives FDA approval for their Denosumab Biosimilars and Secures Global Settlement fresenius.com ↗ |
| 2025-03-26 |
Fresenius Kabi |
Fresenius receives FDA approval for their Denosumab biosimilars and secures global settlement agreement
Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence®** (denosumab-bnht) and Bomyntra®** (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the FDA. fresenius-kabi.com ↗ |
| 2025-03-18 |
Alvotech Swiss AG |
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® alvotech.com ↗ |
| 2025-03-04 |
Celltrion |
Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA® celltrion.com ↗ |
| 2025-03-03 |
Impax Laboratories, LLC |
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA amneal.com ↗ |
| 2024-12-12 |
Roxane Laboratories |
Hikma and Richter announce FDA submission acceptance for Denosumab biosimilar products hikma.com ↗ |
| 2024-11-19 |
Celltrion |
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at ACR Convergence 2024 celltrion.com ↗ |
| 2024-10-30 |
Organon and Co |
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) organon.com ↗ |
| 2024-10-30 |
Shanghai Henlius Biotech |
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) henlius.com ↗ |
| 2024-10-10 |
Alvotech Swiss AG |
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® alvotech.com ↗ |
| 2024-10-08 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA tevapharm.com ↗ |
| 2024-07-19 |
Gedeon Richter Ltd. |
Richter Announces Submission to EMA for Biosimilar Denosumab in Multiple Indications gedeonrichter.com ↗ |
| 2024-07-11 |
Fresenius Kabi |
Fresenius Announces EMA Acceptance for Review of Denosumab Biosimilar Candidates fresenius.com ↗ |
| 2024-07-11 |
Fresenius Kabi |
Fresenius Announces EMA Acceptance for Review of Denosumab Biosimilar Candidates fresenius.com ↗ |
| 2024-07-11 |
Fresenius Kabi |
Fresenius Announces EMA Validation of Marketing Authorization Application for Denosumab Biosimilar Candidates
European Medicines Agency has accepted for review the Marketing Authorization Applications for the biosimilar candidates of Prolia® (denosumab) and Xgeva® (denosumab) fresenius-kabi.com ↗ |
| 2024-07-02 |
Alvotech Swiss AG |
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® alvotech.com ↗ |
| 2024-06-11 |
Alvotech Swiss AG |
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership alvotech.com ↗ |
| 2024-05-27 |
Fresenius Kabi |
Fresenius Announces FDA Acceptance for Review of Denosumab Biosimilar Application fresenius.com ↗ |
| 2024-05-27 |
Fresenius Kabi |
Fresenius Announces FDA Acceptance for Review of Denosumab Biosimilar Application fresenius.com ↗ |
| 2024-05-27 |
Fresenius Kabi |
Fresenius Announces U.S. FDA Acceptance for Review of Biologics License Application for Denosumab Biosimilar Candidate
U.S. Food and Drug Administration has accepted for Review of Biologics License Application for our Denosumab Biosimilar Candidate fresenius-kabi.com ↗ |
| 2024-05-24 |
Organon and Co |
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 organon.com ↗ |
| 2024-05-24 |
Shanghai Henlius Biotech |
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 henlius.com ↗ |
| 2024-05-22 |
Sandoz |
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe sandoz.com ↗ |
| 2024-05-21 |
Alvotech Swiss AG |
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK alvotech.com ↗ |
| 2024-04-30 |
Sandoz |
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars sandoz.com ↗ |
| 2024-04-08 |
Organon and Co |
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints organon.com ↗ |
| 2024-04-08 |
Shanghai Henlius Biotech |
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints henlius.com ↗ |
| 2024-03-05 |
Sandoz |
Sandoz receives FDA approval for first and only denosumab biosimilars sandoz.com ↗ |
| 2024-01-29 |
Alvotech Swiss AG |
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® alvotech.com ↗ |
| 2023-12-11 |
Lotus Pharmaceutical |
Lotus and Intas Announce Strategic Partnership to Commercialize Denosumab Biosimilar in Asia lotuspharm.com ↗ |
| 2023-10-12 |
Impax Laboratories, LLC |
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio amneal.com ↗ |
| 2023-07-12 |
Fresenius Kabi |
Fresenius Kabi’s denosumab biosimilar candidate shows positive clinical trial results fresenius.com ↗ |
| 2023-07-12 |
Fresenius Kabi |
Fresenius Kabi’s denosumab biosimilar candidate shows positive clinical trial results fresenius.com ↗ |
| 2023-07-12 |
Fresenius Kabi |
Fresenius Kabi’s Denosumab Biosimilar Candidate FKS518 Shows Positive Clinical Trial Results
Fresenius Kabi’ denosumab biosimilar candidate FKS518 shows positive clinical trial results. fresenius-kabi.com ↗ |
| 2023-05-25 |
Sandoz |
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA sandoz.com ↗ |
| 2023-05-25 |
Novartis Pharmaceuticals |
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA novartis.com ↗ |
| 2023-05-08 |
Amgen |
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE amgen.com ↗ |
| 2023-02-06 |
Sandoz |
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA sandoz.com ↗ |
| 2023-02-06 |
Novartis Pharmaceuticals |
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA novartis.com ↗ |
| 2022-09-19 |
Sandoz |
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial sandoz.com ↗ |
| 2022-09-19 |
Novartis Pharmaceuticals |
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial novartis.com ↗ |
| 2022-08-25 |
Alvotech Swiss AG |
Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® alvotech.com ↗ |
| 2022-07-20 |
Alvotech Swiss AG |
Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® alvotech.com ↗ |
| 2022-06-13 |
Organon and Co |
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates organon.com ↗ |
| 2021-12-09 |
Gedeon Richter Ltd. |
Richter and Hikma sign exclusive commercialisation and license agreement for denosumab gedeonrichter.com ↗ |
| 2020-11-19 |
BeOne Medicines |
BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma beonemedicines.com ↗ |
| 2020-06-30 |
BeOne Medicines |
BeiGene Begins Commercializing XGEVA® (Denosumab) in China beonemedicines.com ↗ |
| 2020-03-10 |
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
Henlius Received Acceptance Notification for Clinical Trial Application from NMPA for its Denosumab Biosimilar HLX14 fosunpharma.com ↗ |
| 2020-03-09 |
Shanghai Henlius Biotech |
Henlius Received Acceptance Notification for Clinical Trial Application from NMPA for its Denosumab Biosimilar HLX14 henlius.com ↗ |
| 2019-07-22 |
Novartis Pharmaceuticals |
Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis novartis.com ↗ |
| 2018-06-08 |
Amgen |
European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2018-05-21 |
Amgen |
FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2018-04-27 |
Amgen |
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2018-04-03 |
Amgen |
European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma amgen.com ↗ |
| 2018-02-23 |
Amgen |
Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe amgen.com ↗ |
| 2018-02-08 |
Amgen |
Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology amgen.com ↗ |
| 2018-01-05 |
Amgen |
FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma amgen.com ↗ |
| 2017-10-09 |
Amgen |
FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2017-09-08 |
Amgen |
Amgen Highlights The Latest EVENITY™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting amgen.com ↗ |
| 2017-07-31 |
Amgen |
Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2017-06-19 |
Amgen |
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients amgen.com ↗ |
| 2017-06-04 |
Amgen |
Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017 amgen.com ↗ |
| 2017-04-04 |
Amgen |
Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma amgen.com ↗ |
| 2017-03-03 |
Amgen |
Amgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop amgen.com ↗ |
| 2017-03-01 |
Amgen |
Amgen To Present New KYPROLIS® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop amgen.com ↗ |
| 2016-10-20 |
Amgen |
Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients amgen.com ↗ |
| 2016-08-29 |
Amgen |
Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy amgen.com ↗ |
| 2015-12-14 |
Amgen |
Amgen Reacquires All Product Rights To Prolia® (denosumab), XGEVA® (denosumab) And Vectibix® (panitumumab) From GSK In 48 Countries amgen.com ↗ |
| 2015-10-12 |
Amgen |
New Data Show Consistent Safety Profile For Up To 10 Years With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis amgen.com ↗ |
| 2015-10-11 |
Amgen |
New Data Show Greater Bone Mineral Density Gains With Prolia® (Denosumab) Compared With Zoledronic Acid amgen.com ↗ |
| 2015-06-01 |
Amgen |
Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors amgen.com ↗ |
| 2014-12-08 |
Amgen |
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy amgen.com ↗ |
|